BioDelivery Sciences International Inc. (NASDAQ:BDSI)‘s stock had its “buy” rating reissued by equities research analysts at FBR & Co in a report issued on Tuesday.

BDSI has been the topic of a number of other reports. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Tuesday, July 5th. Janney Montgomery Scott reiterated a “hold” rating and issued a $4.00 target price on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. Cantor Fitzgerald reiterated a “hold” rating on shares of BioDelivery Sciences International in a report on Saturday, July 9th. Finally, Piper Jaffray Cos. reiterated a “sell” rating and issued a $4.00 target price on shares of BioDelivery Sciences International in a report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $7.00.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down 2.05% during trading on Tuesday, hitting $2.39. 682,772 shares of the company’s stock were exchanged. BioDelivery Sciences International has a 1-year low of $1.86 and a 1-year high of $7.04. The firm’s market capitalization is $128.20 million. The stock’s 50 day moving average is $2.55 and its 200 day moving average is $2.71.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/biodelivery-sciences-international-inc-bdsi-receives-buy-rating-from-fbr-co.html

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31). The company earned $5 million during the quarter, compared to analyst estimates of $3.35 million. BioDelivery Sciences International had a negative net margin of 109.64% and a negative return on equity of 233.80%. The business’s revenue for the quarter was up 194.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.37) EPS. On average, equities research analysts forecast that BioDelivery Sciences International will post ($1.14) earnings per share for the current year.

In other news, Director William B. Stone sold 16,000 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $2.57, for a total transaction of $41,120.00. Following the sale, the director now owns 122,675 shares in the company, valued at $315,274.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.00% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co. NY raised its stake in BioDelivery Sciences International by 1.8% in the first quarter. Metropolitan Life Insurance Co. NY now owns 32,132 shares of the specialty pharmaceutical company’s stock worth $104,000 after buying an additional 581 shares in the last quarter. Geode Capital Management LLC raised its stake in BioDelivery Sciences International by 1.0% in the first quarter. Geode Capital Management LLC now owns 299,783 shares of the specialty pharmaceutical company’s stock worth $968,000 after buying an additional 3,067 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in BioDelivery Sciences International by 12.0% in the second quarter. Janney Montgomery Scott LLC now owns 61,300 shares of the specialty pharmaceutical company’s stock worth $294,000 after buying an additional 6,550 shares in the last quarter. Squarepoint Ops LLC raised its stake in BioDelivery Sciences International by 22.1% in the first quarter. Squarepoint Ops LLC now owns 41,400 shares of the specialty pharmaceutical company’s stock worth $134,000 after buying an additional 7,500 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in BioDelivery Sciences International by 1.2% in the second quarter. Parametric Portfolio Associates LLC now owns 807,097 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after buying an additional 9,727 shares in the last quarter. Institutional investors and hedge funds own 60.12% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.